Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

May 31, 2019

Conditions
Opioid Use Disorders
Interventions
DRUG

XR-NTX

Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.

BEHAVIORAL

XR-NTX+PN

In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.

BEHAVIORAL

ETAU

Participants assigned to the ETAU group will receive drug education.

Trial Locations (1)

87106

University of New Mexico Center on Alcoholism, Substance Abuse and Addictions, Albuquerque

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alkermes, Inc.

INDUSTRY

lead

University of California, Los Angeles

OTHER